Allscripts Healthcare Solutions Inc. (NASDAQ:MDRX) was the target of a large decrease in short interest in the month of November. As of November 15th, there was short interest totalling 13,718,743 shares, a decrease of 16.8% from the October 31st total of 16,489,242 shares. Currently, 7.5% of the shares of the stock are sold short. Based on an average daily volume of 4,054,051 shares, the days-to-cover ratio is currently 3.4 days.

Several equities research analysts recently commented on the stock. JPMorgan Chase & Co. assumed coverage on shares of Allscripts Healthcare Solutions in a research report on Sunday, October 30th. They issued a “buy” rating and a $15.00 price objective on the stock. Canaccord Genuity set a $17.00 price objective on shares of Allscripts Healthcare Solutions and gave the stock a “buy” rating in a research report on Saturday, November 19th. Zacks Investment Research lowered shares of Allscripts Healthcare Solutions from a “buy” rating to a “hold” rating in a research report on Wednesday, August 10th. Piper Jaffray Cos. reiterated a “neutral” rating and issued a $15.00 price objective (up from $12.00) on shares of Allscripts Healthcare Solutions in a research report on Monday, August 8th. Finally, Deutsche Bank AG boosted their price objective on shares of Allscripts Healthcare Solutions from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Friday, August 5th. Eleven investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Allscripts Healthcare Solutions currently has a consensus rating of “Hold” and a consensus target price of $15.47.

In related news, SVP James Hewitt sold 17,500 shares of the business’s stock in a transaction dated Thursday, September 15th. The shares were sold at an average price of $13.00, for a total value of $227,500.00. Following the sale, the senior vice president now directly owns 158,104 shares in the company, valued at approximately $2,055,352. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Paul Black sold 15,000 shares of the business’s stock in a transaction dated Thursday, September 15th. The stock was sold at an average price of $13.00, for a total transaction of $195,000.00. Following the completion of the sale, the chief executive officer now owns 1,177,009 shares in the company, valued at $15,301,117. The disclosure for this sale can be found here. Insiders own 0.75% of the company’s stock.

A number of institutional investors have recently modified their holdings of the company. Seven Eight Capital LLC bought a new position in shares of Allscripts Healthcare Solutions during the first quarter worth $102,000. Riverhead Capital Management LLC raised its stake in shares of Allscripts Healthcare Solutions by 63.7% in the third quarter. Riverhead Capital Management LLC now owns 8,500 shares of the company’s stock worth $112,000 after buying an additional 3,308 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Allscripts Healthcare Solutions by 23.3% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,618 shares of the company’s stock worth $113,000 after buying an additional 1,626 shares during the last quarter. Two Sigma Securities LLC acquired a new stake in shares of Allscripts Healthcare Solutions during the third quarter worth approximately $134,000. Finally, Harbour Capital Advisors LLC acquired a new stake in shares of Allscripts Healthcare Solutions during the second quarter worth approximately $136,000.

Shares of Allscripts Healthcare Solutions (NASDAQ:MDRX) opened at 10.98 on Thursday. The firm has a 50-day moving average of $11.68 and a 200 day moving average of $12.83. Allscripts Healthcare Solutions has a 12 month low of $9.80 and a 12 month high of $15.78. The firm’s market cap is $2.03 billion.

Allscripts Healthcare Solutions (NASDAQ:MDRX) last issued its quarterly earnings results on Thursday, November 3rd. The company reported $0.14 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.15 by $0.01. The company earned $392.40 million during the quarter, compared to analysts’ expectations of $414.92 million. Allscripts Healthcare Solutions had a positive return on equity of 5.79% and a negative net margin of 0.14%. The company’s revenue for the quarter was up 10.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.13 EPS. On average, equities research analysts anticipate that Allscripts Healthcare Solutions will post $0.56 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2016/12/01/allscripts-healthcare-solutions-inc-mdrx-short-interest-down-16-8-in-november.html.

Allscripts Healthcare Solutions Company Profile

Allscripts Healthcare Solutions, Inc delivers information technology (IT) and services to help healthcare organizations in clinical, financial and operational results. The Company operates through two segments: Clinical and Financial Solutions, and Population Health. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions, which primarily include electronic health record (EHR)-related software, financial and practice management software, related installation, support and maintenance, outsourcing, hosting, revenue cycle management, training and electronic claims administration services.

5 Day Chart for NASDAQ:MDRX

Receive News & Stock Ratings for Allscripts Healthcare Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions Inc. and related stocks with our FREE daily email newsletter.